PARIS (Reuters) - French healthcare company Sanofi said on Wednesday that it had seen positive results in the first study of a high-dose influenza vaccine delivered at the same time as a COVID-19 mRNA booster.
Sanofi said the interim results from the study of Sanofi's Fluzone High-Dose Quadrivalent vaccine administered with Moderna's COVID-19 mRNA investigational booster dose showed the vaccines had similar immunogenicity responses and a similar safety and tolerability profile (https://bit.ly/2YAifV9).
The study, which is being conducted in the United States, includes 300 volunteers aged 65 and older who received two doses of an mRNA COVID-19 vaccine at least five months prior to enrollment.
"These positive results could facilitate the implementation of Northern Hemisphere influenza and COVID-19 booster vaccination campaigns, especially in this high-risk population," said Dr. Michael Greenberg, North America Medical Head for Vaccines at Sanofi.
Reuters Health Information © 2021